Exhibit 10.1


 





AMENDMENT OF VENTURE LOAN AND SECURITY AGREEMENT


 


This AMENDMENT OF VENTURE LOAN AND SECURITY AGREEMENT
(this “Agreement”), dated as of February 2, 2018, is entered into by and among TITAN PHARMACEUTICALS, INC.
(“Borrower”), HORIZON CREDIT II LLC (“Lender”), as assignee of HORIZON TECHNOLOGY FINANCE
CORPORATION (“Horizon”), and Horizon as Collateral Agent.


 


RECITALS


 


A.                 
Borrower and Lender are parties to a certain Venture Loan and Security Agreement dated as of July 27, 2017 (as amended, restated,
supplemented or otherwise modified from time to time, the “Loan Agreement”) pursuant to which, among other
things, Horizon (i) provided a loan to Borrower as evidenced by a certain Secured Promissory Note (Loan A) executed by Borrower
in favor of Horizon, dated July 27, 2017, in the original principal amount of Three Million Five Hundred Thousand and 00/100 Dollars
($3,500,000.00) (“Loan A Note”), (ii) provided a loan to Borrower as evidenced by a certain Secured Promissory
Note (Loan B) executed by Borrower in favor of Horizon, dated July 27, 2017, in the original principal amount of Three Million
Five Hundred Thousand and 00/100 Dollars ($3,500,000.00) (“Loan B Note” and collectively with the Loan A Note,
the “Notes”) and (v) has been granted a security interest in all assets of Borrower, except, prior to the date
hereof, with respect to Borrower’s Intellectual Property (as defined in the Loan Agreement).


 


B.                 
Horizon has assigned all of its right, title and interest in and to the Notes to Lender pursuant to that certain Assignment of
Notes Receivable dated as of July 27, 2017.


 


C.                 
Borrower and Lender desire to amend the Loan Agreement to, among other things, grant Lender a security interest in Borrower’s
Intellectual Property, and provide for the prepayment of a portion of the Notes, but only to the extent, and in accordance with
the terms, and subject to the conditions, set forth herein.


 


AGREEMENT


 


NOW,
THEREFORE, in consideration of the above recitals and for other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, Borrower, Lender and Collateral Agent hereby agree as follows:


 


1.                 
Definitions; Interpretation. Unless otherwise defined herein, all capitalized terms used herein and defined in the
Loan Agreement shall have the respective meanings given to those terms in the Loan Agreement. Other rules of construction set forth
in the Loan Agreement, to the extent not inconsistent with this Agreement, apply to this Agreement and are hereby incorporated
by reference.


 


2.                  Confirmation.
Borrower hereby acknowledges and agrees that: (i) the Loan Agreement sets forth the legal, valid, binding and continuing
obligations of Borrower to Lender, (ii) the Obligations to Lender under the Loan Agreement are secured by validly perfected
security interests in all assets of Borrower (except, prior to the date of this Agreement, with respect to Borrower’s
Intellectual Property), the effectiveness and validity of which are hereby confirmed and (iii) Borrower has no cause of
action, claim, defense or set-off against Lender or any of its affiliates and subsidiaries, officers, directors,
employees, shareholders, agents and representatives (“Related Parties”), arising on or prior to the date
of this Agreement, in any way regarding or relating to the Loan Agreement or Lender’s or its Related Parties’
actions thereunder and to the extent any such cause of action, claim, defense or set-off ever existed, whether foreseen or
unforeseen, it is waived and Lender and its Related Parties are released from any such causes of action, claims, defenses or
rights of set-off of Borrower.


 






     


     


    

 


		3.	Prepayment.



 


		(a)	Borrower and Lender hereby agree that in consideration of Lender’s
and Borrower’s agreements contained herein, Borrower shall, no later than two (2) Business Days following the execution of
this Agreement, prepay a portion of the outstanding principal amount of (i) Loan A in an amount equal to One Million Five Hundred
Thousand Dollars ($1,500,000) and (ii) Loan B in an amount equal to One Million Five Hundred Thousand Dollars ($1,500,000) (collectively,
the “First Prepayment”). Lender and Borrower acknowledge that after giving effect to the First Prepayment, the outstanding
principal balance of (i) Loan A shall be Two Million Dollars ($2,000,000) and (ii) Loan B shall be Two Million Dollars ($2,000,000).



 


		(b)	Borrower and Lender hereby agree that in consideration of Lender’s
and Borrower’s agreements contained herein, Borrower shall, no later than two (2) Business Days following the occurrence
of a Specified Event (as hereafter defined), prepay a portion of the outstanding principal amount of (i) Loan A in an amount equal
to Five Hundred Thousand Dollars ($500,000) and (ii) Loan B in an amount equal to Five Hundred Thousand Dollars ($500,000) (collectively,
the “Second Prepayment”). Lender and Borrower acknowledge that, assuming no additional prepayments have theretofore
been made since the date of the First Prepayment, after giving effect to the Second Prepayment, the outstanding principal balance
of (i) Loan A shall be One Million Five Hundred Thousand Dollars ($1,500,000) and (ii) Loan B shall be One Million Five Hundred
Thousand Dollars ($1,500,000). For purposes hereof, the term “Specified Event” means the earlier to occur of (a) the
receipt by Borrower of cash proceeds in an amount not less than Five Million Dollars ($5,000,000) as a result of the sale (or series
of related sales) by Borrower of its Equity Securities on or after the date of this Agreement and (b) May 14, 2018.



 


		(c)	Borrower and Lender hereby agree that notwithstanding anything contained
in Section 2.3(b) of the Loan Agreement to the contrary, each of the First Prepayment and Second Prepayment shall be made without
premium or penalty.



 






    - 2 -


     


    

 








		4.	Amendments to Loan Agreement.



 


		(a)	Borrower and Lender hereby agree that Section 4.1 of the Loan Agreement shall be deleted in its
entirety and replaced with the following:



 


“4.1 Grant of Security
Interests. Borrower grants to Collateral Agent and Lender a valid, continuing security interest in all presently existing and
hereafter acquired or arising Collateral in order to secure prompt, full and complete payment of any and all Obligations and in
order to secure prompt, full and complete performance by Borrower of each of its covenants and duties under each of the Loan Documents
(other than the Warrants). The “Collateral” shall mean and include all right, title, interest, claims and demands of
Borrower in the following:


 


(a)  
All goods (and embedded computer programs and supporting information included within the definition of “goods”
under the Code) and equipment now owned or hereafter acquired, including all laboratory equipment, computer equipment, office equipment,
machinery, fixtures, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing, and all attachments,
accessories, accessions, replacements, substitutions, additions, and improvements to any of the foregoing, wherever located;


 


(b)  
All inventory now owned or hereafter acquired, including all merchandise, raw materials, parts, supplies, packing and shipping
materials, work in process and finished products including such inventory as is temporarily out of Borrower’s custody or
possession or in transit and including any returns upon any accounts or other proceeds, including insurance proceeds, resulting
from the sale or disposition of any of the foregoing and any documents of title representing any of the above, and Borrower’s
books relating to any of the foregoing;


 


(c)  
All contract rights and general intangibles (including Intellectual Property), now owned or hereafter acquired, including
goodwill, license agreements (subject to the terms thereof), franchise agreements, blueprints, drawings, purchase orders, customer
lists, route lists, infringements, claims, software, computer programs, computer disks, computer tapes, literature, reports, catalogs,
design rights, income tax refunds, payment intangibles, commercial tort claims, payments of insurance and rights to payment of
any kind;


 


(d)  
All now existing and hereafter arising accounts, contract rights, royalties, license rights, license fees and all other
forms of obligations owing to Borrower arising out of the sale or lease of goods, the licensing of technology or the rendering
of services by Borrower (subject, in each case, to the contractual rights of third parties to require funds received by Borrower
to be expended in a particular manner), whether or not earned by performance, and any and all credit insurance, guaranties, and
other security therefor, as well as all merchandise returned to or reclaimed by Borrower and Borrower’s books relating to
any of the foregoing;


 




    - 3 -


     


    

 


(e)  
All documents, cash, deposit accounts, letters of credit and letters of credit rights (whether or not the letter of credit
is evidenced by a writing) and other supporting obligations, certificates of deposit, instruments, promissory notes, chattel paper
(whether tangible or electronic) and investment property, including all securities, whether certificated or uncertificated, security
entitlements, securities accounts, commodity contracts and commodity accounts, and all financial assets held in any securities
account or otherwise, wherever located, now owned or hereafter acquired and Borrower’s books relating to the foregoing; and


 


(f)   
To the extent not covered by clauses (a) through (e), all other personal property of the Borrower, whether tangible or intangible,
and any and all rights and interests in any of the above and the foregoing and, any and all claims, rights and interests in any
of the above and all substitutions for, additions and accessions to and proceeds thereof, including insurance, condemnation, requisition
or similar payments and proceeds of the sale or licensing of Intellectual Property.”


 


		(b)	Borrower and Lender hereby agree that Section 4.3 of the Loan Agreement shall be deleted in its
entirety and replaced with the following:



 


“4.3 Duration of
Security Interest. Collateral Agent’s and Lender’s security interest in the Collateral shall continue until the
indefeasible payment in full and the satisfaction of all Obligations, and termination of Lender’s commitment to fund the
Loans, whereupon such security interest shall terminate. Collateral Agent and Lender shall, at Borrower’s sole cost and expense,
execute such further documents and take such further actions as may be reasonably necessary to make effective the releases contemplated
by this Section 4.3 (including with respect to Collateral Agent’s and Lender’s security interest in Borrower’s
Intellectual Property as contemplated by the immediately succeeding sentence), including duly authorizing and delivering termination
statements for filing in all relevant jurisdictions under the Code and Intellectual Property security interest releases for filing
with the United States Patent and Trademark Office. Notwithstanding the foregoing, Collateral Agent’s and Lender’s
security interest in Borrower’s Intellectual Property shall automatically terminate if Borrower provides Lender with evidence
reasonably satisfactory to Lender that Borrower has, during any twelve (12) consecutive month period commencing on January 1, 2018
and continuing through December 31, 2019, received cash royalties and/or sales milestone payments in an aggregate amount of not
less than Five Hundred Thousand Dollars ($500,000) as the result of sales of Probuphine in the United States and Canada pursuant
to a license agreement with a third party.”


 


		(c)	Borrower and Lender hereby agree that the following shall be added to the Loan Agreement as new
Section 4.9:



 


“4.9 Intellectual
Property. Borrower shall promptly notify Lender within five (5) Business Days after the federal registration or filing by
Borrower of any patent or patent application, or trademark or trademark application, or copyright or copyright application and
shall promptly execute and deliver to Lender any grants of security interests in same, in form reasonably acceptable to Lender,
to file with the United States Patent and Trademark Office or the United States Copyright Office, as applicable.”


 






    - 4 -


     


    

 


		(d)	Borrower and Lender hereby agree that the following shall be added to the Loan Agreement as new
Section 6.12:



 


“6.12 Equity Financing.


 


		(a)	Borrower shall provide Lender, on or after February 1, 2018, but on or prior
to February 28, 2018, a written summary of the terms and conditions of a transaction pursuant to which Borrower shall, if such
transaction is consummated, receive, on or after February 1, 2018, cash proceeds of not less than Ten Million Dollars ($10,000,000)
as a result of the sale of Borrower’s Equity Securities (the “2018 Equity Financing”), which summary shall
be reasonably acceptable to Lender and shall set forth, in reasonable detail, the terms of such 2018 Equity Financing and, to the
extent known at the time such summary is delivered to Lender, the identity of the individuals or entities purchasing not less than
seventy-five percent (75%) of the Equity Securities being sold in such transaction in the aggregate (the “Designated Equity
Investors”). In the event all Designated Equity Investors are not known to Borrower at the time Borrower delivers the
2018 Equity Financing summary to Lender, Borrower shall, within two (2) Business Days of obtaining such information,
provide Lender in writing the names and identities of each Designated Equity Investor.”






 


		(b)	If stockholder approval of the 2018 Equity Financing is required by Borrower’s
charter or any applicable law, Borrower shall provide Lender, on or prior to March 15, 2018, with evidence reasonably satisfactory
to Lender, that Borrower has filed a preliminary proxy statement with the U.S. Securities and Exchange Commission.”






 


		(e)	Borrower and Lender hereby agree that Section 8.2 of the Loan Agreement shall
be deleted in its entirety and replaced with the following:



 


“8.2
Certain Covenant Defaults. If Borrower fails to perform any obligation arising under Sections 6.5, 6.8 or 6.12, or violates
any of the covenants contained in Section 7 of this Agreement.”


 


		5.	Amendments to Notes.



 


		(a)	Borrower and Lender agree that the fifth (5th)
sentence of the second paragraph of the Secured Promissory Note (Loan A) dated July 27, 2017 in the original principal amount of
$3,500,000 made by Borrower in favor of Lender is hereby amended and restated in its entirety to provide as follows:



 




    - 5 -


     


    

 


“Commencing on January
1, 2019, and continuing on the first day of each month thereafter (each, a “Principal and Interest Payment Date”
and, collectively with each Interest Payment Date, each, a Payment Date”), Borrower shall make to Lender thirty (30) equal
payments of principal in the amount of Sixty-Six Thousand Six Hundred Sixty-Six Dollars and Sixty-Six Cents ($66,666.66) (each,
a “Principal Amortization Amount”) plus accrued interest on the then outstanding principal amount due hereunder. On
the first day of the first month following Lender’s receipt of the Second Prepayment (as defined in the Amendment of Venture
Loan and Security Agreement dated as of January , 2018 by and among Borrower, Lender and Collateral Agent), each Principal Amortization
Amount shall be decreased to Fifty Thousand Dollars ($50,000.00).”


 


		(b)	Borrower and Lender agree that the fifth (5th)
sentence of the second paragraph of the Secured Promissory Note (Loan B) dated July 27, 2017 in the original principal amount of
$3,500,000 made by Borrower in favor of Lender is hereby amended and restated in its entirety to provide as follows:



 


“Commencing on January
1, 2019, and continuing on the first day of each month thereafter (each, a “Principal and Interest Payment Date”
and, collectively with each Interest Payment Date, each, a Payment Date”), Borrower shall make to Lender thirty (30) equal
payments of principal in the amount of Sixty-Six Thousand Six Hundred Sixty-Six Dollars and Sixty-Six Cents ($66,666.66) (each,
a “Principal Amortization Amount”) plus accrued interest on the then outstanding principal amount due hereunder. On
the first day of the first month following Lender’s receipt of the Second Prepayment (as defined in the Amendment of Venture
Loan and Security Agreement dated as of January , 2018 by and among Borrower, Lender and Collateral Agent), each Principal Amortization
Amount shall be decreased to Fifty Thousand Dollars ($50,000.00).”


 


6.              Lend
er’s and Collateral Agent’s Acknowledgments . Lender and Collateral Agent hereby acknowledge that (a) Borrower’s
grant to Collateral Agent and Lender of a security interest in Borrower’s Intellectual Property shall not constitute a breach
of Section 7.14 of the Loan Agreement and (b) during the Specified Period (as hereafter defined), none of the following shall
constitute or form the basis upon which Lender may at any time declare a Default or an Event of Default under the Loan Agreement
(including, without limitation, under Section 8.4 thereof) or under any other Loan Document: (i) the level of Probuphine sales
or royalties related thereto, (ii) the valuation of Probuphine, or (iii) the termination or amendment of the existing Probuphine
license agreement. For purposes hereof, the term “Specified Period” means the period commencing as of the date of
the Loan Agreement and ending on the date that is twelve (12) months after the date of this Agreement.


 


		7.	Representations and Warranties.



 


		(a)	At and as of the date of this Agreement and both prior to and after giving
effect to this Agreement, each of the representations and warranties contained in the Loan Agreement is true and correct in all
material respects (except where such representations and warranties
expressly relate to an earlier date, in which case such representations and warranties are true and correct in all material respects
as of such earlier date).



 




    - 6 -


     


    




 


		(b)	Borrower has all necessary power and authority to execute, deliver, and
perform in accordance with the terms thereof, this Agreement. Borrower has all requisite power and authority to own and operate
its Property and to carry on its business as now conducted.



 


		(c)	No Default or Event of Default has occurred under the Loan Agreement or
the other Loan Documents and is continuing or will exist immediately after giving effect to this Agreement.



 


8.             Covenants of Borrower. Borrower agrees that, in connection with its execution and delivery of this Agreement, Borrower
shall deliver to Lender each of the following items, and the failure by Borrower to deliver any of these items shall be a Default
under the Loan Agreement:


 


		(a)	Grants of security interest in Borrower’s Intellectual Property, in
the form attached hereto as Exhibit A, each duly executed by Borrower;



 


		(b)	Within five (5) Business Days following Borrower’s receipt thereof
from Lender, such other documents, instruments and agreements, including UCC financing statement amendments and evidence of filings
with the United States Patent and Trademark Office and the United States Copyright Office, in each case in form and substance reasonably
acceptable to Borrower, as Lender shall reasonably request to evidence the perfection and priority of the security interests granted
to Collateral Agent and Lender in Borrower’s Intellectual Property; and



 


		(c)	Borrower’s payment of Lender’s legal expenses in the amount
of Five Thousand and 00/100 Dollars ($5,000) incurred in connection with the drafting, negotiation and execution of this Agreement
and the documents, instruments, agreements and financing statements referred to in Sections 6(a) and (b) of this Agreement.



 


9.             Effect
of Agreement. On and after the date hereof, each reference to the Loan Agreement in the Loan Agreement or in any other document
shall mean the Loan Agreement as amended by this Agreement. Except as expressly provided hereunder, the execution, delivery and
effectiveness of this Agreement shall not operate as a waiver of any right, power, or remedy of Lender, nor constitute a waiver
of any provision of the Loan Agreement. Except to the limited extent expressly provided herein, nothing contained herein shall,
or shall be construed to (nor shall the Borrower ever argue to the contrary) (i) modify the Loan Agreement, any Note or any other
Loan Document (ii) modify, waive, impair, or affect any of the covenants, agreements, terms, and conditions thereof, or (iii)
waive the due keeping, observance and/or performance thereof, each of which is hereby ratified and confirmed by the Borrower.
Except as amended above, the Loan Agreement remains in full force and effect. Borrower acknowledges and agrees that the
failure to make any payment required under this Agreement shall constitute an Event of Default under the Loan Agreement.


 






    - 7 -


     


    

 


10.             Headings.
Headings in this Agreement are for convenience of reference only and are not part of the substance hereof.


 


11.             Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Connecticut
without reference to conflicts of law rules.


 


12.             Counterparts. This Agreement may be executed in any number of counterparts, including by electronic or facsimile
transmission, each of which when so delivered shall be deemed an original, but all such counterparts taken together shall constitute
but one and the same instrument.


 


13.             Integration. This Agreement and the Loan Documents constitute and contain the entire agreement of Borrower, Collateral
Agent and Lender with respect to their respective subject matters, and supersede any and all prior agreements, correspondence and
communications.


 


[Remainder of page intentionally left blank]


 




    - 8 -


     


    

 


IN WITNESS WHEREOF, Borrower,
Lender and Collateral Agent have caused this AMENDMENT OF VENTURE LOAN AND SECURITY AGREEMENT to be executed as of the day and
year first above written.


 





	BORROWER:	 	 	 
	 	 	 	 	 
	TITAN PHARMACEUTICALS, INC.	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	By:	/s/ Sunil Bhonsle 	 	 	 
	Name: 	Sunil Bhonsle	 	 	 
	Title:	President & CEO	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	LENDER:	 	COLLATERAL AGENT:
	HORIZON CREDIT II LLC	 	HORIZON TECHNOLOGY FINANCE CORPORATION
	 	 	 
	 	 	 
	By:	/s/ Robert D. Pomeroy, Jr.	 	By:	/s/ Robert D. Pomeroy, Jr.
	Robert D. Pomeroy, Jr. 	 	Robert D. Pomeroy, Jr.
	Chief Executive Officer	 	Chief Executive Officer


 





(Signature page to Amendment to Venture Loan and Security
Agreement)




  






     


     


    

 







GRANT OF SECURITY
INTEREST PATENTS


 


THIS GRANT OF SECURITY INTEREST,
dated as of February 2, 2018, is executed by TITAN PHARMACEUTICALS, INC., a Delaware corporation with an address of 400 Oyster
Point Blvd., Suite 505, South San Francisco, CA 94080 (“Debtor”), in favor of HORIZON CREDIT II LLC, as assignee
of HORIZON TECHNOLOGY FINANCE CORPORATION, a Delaware corporation with an address of 312 Farmington Avenue, Farmington, Connecticut
06032 (“Secured Party”).


 


A.                
Pursuant to a certain Venture Loan and Security Agreement, dated as of July 27, 2017 (as amended, restated, supplemented
or otherwise modified from time to time, (the “Agreement”) by and between Debtor and the Secured Party, the
Secured Party has agreed to extend credit to Debtor upon the terms and subject to the conditions set forth therein;


 


B.                
Debtor owns the patents and/or applications for patents, more particularly described on Schedules 1-A and 1-B annexed
hereto as part hereof (collectively, the “Patents”);


 


C.                
Pursuant to the Agreement, Debtor has granted to Secured Party a security interest in all right, title and interest of Debtor
in and to the Patents, together with any reissue, continuation, continuation-in-part or extension thereof, and all proceeds thereof,
including any and all causes of action which may exist by reason of infringement thereof for the full term of the Patents (the
“Collateral”), to secure the prompt payment, performance and observance of the Obligations (as defined in the
Agreement);


 


NOW, THEREFORE, for good and
valuable consideration, receipt of which is hereby acknowledged, Debtor does hereby further grant to Secured Party a security interest
in the Collateral to secure the prompt payment, performance and observance of the Obligations.


 


Debtor
does hereby further acknowledge and affirm that the rights and remedies of Secured Party with respect to the security interest
in the Collateral granted hereby are more fully set forth in the Agreement, the terms and provisions of which are hereby incorporated
herein by reference as if fully set forth herein.


 


IN WITNESS WHEREOF, Debtor
has caused this instrument to be executed as of the day and year first written above.


 





	 	TITAN PHARMACEUTICALS, INC.
	 	 	 
	 	 	 
	 	By:	/s/ Sunil Bhonsle
	 	Name: Sunil Bhonsle
	 	Title: President & CEO







 




     


     


    

 


SCHEDULE 1-A TO GRANT OF SECURITY INTEREST


PATENTS


 


	Patent	 	Title	 	Docket No.	 	Owner	 	Patent Number	 	Grant Date
	US 
United States	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE	 	 30414- 
20008.00	 	 Titan Pharmaceuticals, Inc.	 	 7736665	 	 06-15-2010
	AU 
Australian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE	 	 30414- 
20008.41	 	 Titan Pharmaceuticals, Inc.	 	 2003240493	 	 09-25-2008
	CA 
Canadian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE	 	 30414- 
20008.42	 	 Titan Pharmaceuticals, Inc.	 	 2487577	 	 11-18-2014
	IN 
Indian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE	 	 30414- 
20008.43	 	 Titan Pharmaceuticals, Inc.	 	 214622	 	 02-13-2008
	JP 
Japanese	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE	 	30414- 
20008.44	 	 Titan Pharmaceuticals, Inc.	 	 4668611	 	 01-21-2011
	MX 
Mexican	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE	 	30414- 
20008.45	 	 Titan Pharmaceuticals, Inc.	 	 266637	 	 05-11-2009
	NZ 
New Zealand	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE	 	30414- 
20008.46	 	 Titan Pharmaceuticals, Inc.	 	 536965	 	 06-07-2007
	AU 
Australian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE	 	30414- 
20008.50	 	 Titan Pharmaceuticals, Inc.	 	 2008212011	 	 09-09-2010






 






     


     


    




 


	US 
United States	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.02	 	 Titan Pharmaceuticals, Inc.	 	 8,852,623	 	 10-07-2014
	US 
United States	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.03	 	 Titan Pharmaceuticals, Inc.	 	 9,278,163	 	 03-08-2016
	AU 
Australian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.41	 	 Titan Pharmaceuticals, Inc.	 	 2004228017	 	 05-27-2010
	CA 
Canadian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.42	 	 Titan Pharmaceuticals, Inc.	 	 2520613	 	 12-04-2012
	IL 
Israeli	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.45	 	 Titan Pharmaceuticals, Inc.	 	 171115	 	 01-30-2016
	JP 
Japanese	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.46	 	 Titan Pharmaceuticals, Inc.	 	 5064794	 	 08-17-2012
	KR 
South Korean	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.47	 	 Titan Pharmaceuticals, Inc.	 	 101152183	 	 05-25-2012
	MX 
Mexican	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.48	 	 Titan Pharmaceuticals, Inc.	 	 284457	 	 03-08-2011






 






     


     


    

 


	NZ 
New Zealand	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.49	 	 Titan Pharmaceuticals, Inc.	 	 542548	 	 08-13-2009
	ZA 
South African	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.50	 	 Titan Pharmaceuticals, Inc.	 	 200507877	 	 10-31-2007
	EP 
European	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.51	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	HK 
Hong Kong	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.52	 	 Titan Pharmaceuticals, Inc.	 	 1083682	 	 08-26-2011
	MX 
Mexican	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.54	 	 Titan Pharmaceuticals, Inc.	 	 294075	 	 01-03-2012
	AT 
Austrian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.55	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	BE 
Belgian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.56	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	BG 
Bulgarian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.57	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011






 






     


     


    

 


	CH 
Swiss	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.58	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	CY 
Cyprian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.59	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	CZ 
Czech Republic	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.60	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	DE 
German	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.61	 	 Titan Pharmaceuticals, Inc.	 	 6020040315125	 	 02-23-2011
	DK 
Danish	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.62	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	EE 
Estonian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.63	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	ES 
Spanish	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.64	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	FI 
Finnish	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.65	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011






 






     


     


    

 


	FR 
French	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.66	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	GB 
British	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.67	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	GR 
Greek	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.68	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	HU 
Hungarian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.69	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	IE 
Irish	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.70	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	IT 
Italian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.71	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	LU 
Luxembourg	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.72	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	MC 
Monaco	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.73	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011






 






     


     


    

 


	NL 
Dutch	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.74	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	PL 
Polish	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.75	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	PT 
Portuguese	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.76	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	RO 
Romanian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.77	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	SE 
Swedish	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.78	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	SI 
Slovenian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.79	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	SK 
Slovak Republic	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.80	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011
	TR 
Turkish	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.81	 	 Titan Pharmaceuticals, Inc.	 	 1610791	 	 02-23-2011






 






     


     


    

 


	JP 
Japanese	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.82	 	 Titan Pharmaceuticals, Inc.	 	 5608581	 	 09-05-2014
	CN 
Chinese	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.83	 	 Titan Pharmaceuticals, Inc.	 	 ZL2012101671235	 	 12-31-2014
	HK 
Hong Kong	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.84	 	 Titan Pharmaceuticals, Inc.	 	 HK1177895	 	 10-23-2015
	AU 
Australian	 	HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY	 	30414- 
20045.41	 	 Titan Pharmaceuticals, Inc.	 	 2011227289	 	 05-05-2016
	JP 
Japanese	 	HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY	 	30414- 
20045.46	 	 Titan Pharmaceuticals, Inc.	 	 5869551	 	 01-15-2016
	SG 
Singaporean	 	HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY	 	30414- 
20045.49	 	 Titan Pharmaceuticals, Inc.	 	 184059	 	 04-16-2015
	JP 
Japanese	 	HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY	 	30414- 
20045.52	 	 Titan Pharmaceuticals, Inc.	 	 6022649	 	 10-14-2016




 



     


     


    

 


SCHEDULE 1-B TO GRANT OF SECURITY INTEREST


 





PATENT APPLICATIONS


 


	Patent 

Application	 	Title	 	Docket No.	 	Owner	 	Application 

Number	 	Application 

Date
	US 
United States	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE	 	[at Choate, Hall 
& Stewart; no MoFo docket no.]	 	 Titan Pharmaceuticals, Inc.	 	 15/667,770	 	 08-03-2017
	EP 
European	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE	 	30414- 
20008.51	 	 Titan Pharmaceuticals, Inc.	 	 121934350	 	 06-02-2003
	HK 
Hong Kong	 	ADMINISTRATION OF BUPRENORPHINE IN A POLYMERIC MATRIX	 	30414- 
20008.52	 	 Titan Pharmaceuticals, Inc.	 	 131089542	 	 06-02-2003
	IN 
Indian	 	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	 	30414- 
20009.53	 	 Titan Pharmaceuticals, Inc.	 	 1193KOLNP2008	 	 03-24-2008






 






     


     


    

 


	US 
United States	 	HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY	 	30414- 
20045.00	 	 Titan Pharmaceuticals, Inc.	 	 13/634,535	 	 03-16-2011
	US 
United States	 	HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY	 	30414- 
20045.01	 	 Titan Pharmaceuticals, Inc.	 	 13/802,504	 	 03-16-2011
	CA 
Canadian	 	HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY	 	30414- 
20045.42	 	 Titan Pharmaceuticals, Inc.	 	 2792179	 	 03-16-2011
	EP 
European	 	HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY	 	30414- 
20045.43	 	 Titan Pharmaceuticals, Inc.	 	 117569574	 	 03-16-2011
	HK 
Hong Kong	 	HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY	 	30414- 
20045.44	 	 Titan Pharmaceuticals, Inc.	 	 131086402	 	 03-16-2011
	IN 
Indian	 	HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY	 	30414- 
20045.45	 	 Titan Pharmaceuticals, Inc.	 	 8733/DELNP/2012	 	 03-16-2011
	KR 
South Korean	 	HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY	 	30414- 
20045.47	 	 Titan Pharmaceuticals, Inc.	 	 1020127026810	 	 03-16-2011
	MX 
Mexican	 	HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY	 	30414- 
20045.48	 	 Titan Pharmaceuticals, Inc.	 	 MX/a/2012/010611	 	 03-16-2011
	ZA 
South African	 	HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY	 	30414- 
20045.50	 	 Titan Pharmaceuticals, Inc.	 	 201206563	 	 03-16-2011
	SG 
Singaporean	 	HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY	 	30414- 
20045.51	 	 Titan Pharmaceuticals, Inc.	 	 10201501964Q	 	 03-16-2011
	PCT 
International (PCT)	 	IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE	 	30414- 
20046.40	 	 Titan Pharmaceuticals, Inc.	 	 PCT/US2017/055432	 	 10-05-2017
	US 
United States	 	IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE	 	30414- 
30046.00	 	 Titan Pharmaceuticals, Inc.	 	 62/404,643	 	 10-05-2016



 








     


     


    

 





GRANT OF SECURITY
INTEREST TRADEMARKS


 


THIS GRANT OF SECURITY INTEREST,
dated as February 2, 2018, is executed by TITAN PHARMACEUTICALS, INC., a Delaware corporation with an address of 400 Oyster Point
Blvd., Suite 505, South San Francisco, CA 94080 (“Debtor”), in favor of HORIZON CREDIT II LLC, as assignee of
HORIZON TECHNOLOGY FINANCE CORPORATION, a Delaware corporation with an address of 312 Farmington Avenue, Farmington, Connecticut
06032 (“Secured Party”).


 


A.                
Pursuant to a certain Venture Loan and Security Agreement, dated as of July 27, 2017 (as amended, restated, supplemented
or otherwise modified from time to time, (the “Agreement”) by and between Debtor and the Secured Party, the
Secured Party has agreed to extend certain credit facilities to Debtor upon the terms and subject to the conditions set forth therein;


 


B.                
Debtor owns the registered trademarks, service marks (and applications and registrations therefor), of the United States,
more particularly described on Schedules 1-A and 1-B annexed hereto as part hereof (collectively, the “Trademarks”);


 


C.                
Pursuant to the Agreement, Debtor has granted to Secured Party a security interest in all right, title and interest of Debtor
in and to the Trademarks, together with associated goodwill, and all proceeds thereof, including any and all causes of action which
may exist by reason of infringement thereof for the full term of the Trademarks (the “Collateral”), to secure
the prompt payment, performance and observance of the Obligations (as defined in the Agreement);


 


NOW, THEREFORE, for good
and valuable consideration, receipt of which is hereby acknowledged, Debtor does hereby further grant to Secured Party a security
interest in the Collateral to secure the prompt payment, performance and observance of the Obligations.


 


Debtor
does hereby further acknowledge and affirm that the rights and remedies of Secured Party with respect to the security interest
in the Collateral granted hereby are more fully set forth in the Agreement, the terms and provisions of which are hereby incorporated
herein by reference as if fully set forth herein.


 


IN WITNESS WHEREOF, Debtor
has caused this instrument to be executed as of the day and year first written above.


 





	 	TITAN PHARMACEUTICALS, INC.
	 	 	 
	 	 	 
	 	By:	/s/ Sunil Bhonsle
	 	Name: Sunil Bhonsle
	 	Title: President & CEO


 









     


     


    

 





SCHEDULE 1-A TO GRANT OF SECURITY INTEREST


 


TRADEMARKS


 


	
         

        Trademark
	
         

        Country
	
         

        Owner
	
         

        Registration Number
	
         

        Registration Date

	
         

        T & DESIGN

         

        
	
         

        Japan
	
         

        Titan Pharmaceuticals, Inc.
	
         

        4656286
	
         

        03/20/2003

	
         

        PROBUPHINE.
	
         

        United States of America
	
         

        Titan Pharmaceuticals, Inc.
	
         

        4,102,980
	
         

        02/21/2012

	
         

        PROBUPHINE
	
         

        European Union
	
         

        Titan Pharmaceuticals, Inc.
	
         

        002707743
	
         

        10/27/2003

	
         

        PROBUPHINE
	
         

        Japan
	
         

        Titan Pharmaceuticals, Inc.
	
         

        4707954
	
         

        09/05/2003

	
         

        PROBUPHINE
	
         

        Switzerland
	
         

        Titan Pharmaceuticals, Inc.
	
         

        502931
	
         

        05/17/2002

	
         

        PROBUPHINE
	
         

        European Union
	
         

        Titan Pharmaceuticals, Inc.
	
         

        010891646
	
         

        10/11/2012

	
         

        PROBUPHINE
	
         

        Switzerland
	
         

        Titan Pharmaceuticals, Inc.
	
         

        631889
	
         

        07/16/2012

	
         

        PROBUPHINE
	
         

        Australia
	
         

        Titan Pharmaceuticals, Inc.
	
         

        1545572
	
         

        12/16/2013

	
         

        PROBUPHINE
	
         

        Mexico
	
         

        Titan Pharmaceuticals, Inc.
	
         

        1380691
	
         

        07/03/2013






 






     


     


    

 


	
         

        TITAN PHARMACEUTICALS
	
         

        Japan
	
         

        Titan Pharmaceuticals, Inc.
	
         

        2002045667
	
         

        01/10/2003

	
         

        PRONEURA
	
         

        Japan
	
         

        Titan Pharmaceuticals, Inc.
	
         

        4821226
	
         

        11/26/2004

	
         

        PRONEURA
	
         

        Switzerland
	
         

        Titan Pharmaceuticals, Inc.
	
         

        524391
	
         

        08/17/2004

	
         

        PRONEURA
	
         

        European Union
	
         

        Titan Pharmaceuticals, Inc.
	
         

        004940359
	
         

        02/13/2007

	
         

        T LOGO PLUS INNOVATIONS IN MEDICINE

         

        
	
         

        Switzerland
	
         

        Titan Pharmaceuticals, Inc.
	
         

        532111
	
         

        02/25/2005

	
         

        T LOGO PLUS INNOVATIONS IN MEDICINE

         

        
	
         

        Japan
	
         

        Titan Pharmaceuticals, Inc.
	
         

        4933523
	
         

        03/03/2006

	
         

        T LOGO PLUS INNOVATIONS IN MEDICINE

         

        
	
         

        European Union
	
         

        Titan Pharmaceuticals, Inc.
	
         

        004591483
	
         

        08/22/2006

	
         

        BUPLANT
	
         

        Madrid Protocol
	
         

        Titan Pharmaceuticals, Inc.
	
         

        IR1320700
	
         

        08/26/2016






 






    -2-


     


    

 


	
         

        BUPLANT
	
         

        Australia
	
         

        Titan Pharmaceuticals, Inc.
	
         

        IR1320700
	
         

        08/26/2016

	
         

        BUPLANT
	
         

        European Union
	
         

        Titan Pharmaceuticals, Inc.
	
         

        IR1320700
	
         

        08/26/2016

	
         

        BUPLANT
	
         

        Mexico
	
         

        Titan Pharmaceuticals, Inc.
	
         

        IR1320700
	
         

        08/26/2016

	
         

        BUPLANT
	
         

        Switzerland
	
         

        Titan Pharmaceuticals, Inc.
	
         

        IR1320700
	
         

        08/26/2016

	
         

        T & DESIGN

         

        
	
         

        Madrid Protocol
	
         

        Titan Pharmaceuticals, Inc.
	
         

        IR1370158
	
         

        06/16/2017

	
         

        TITAN PHARMACEUTICALS & DESIGN

         

        
	
         

        Madrid Protocol
	
         

        Titan Pharmaceuticals, Inc.
	
         

        IR1366454
	
         

        06/16/2017






 






    -3-


     


    

 


SCHEDULE 1-B TO GRANT OF SECURITY INTEREST


 


TRADEMARK APPLICATIONS


 


	
         

        Trademark Application
	
         

        Country
	
         

        Owner
	
         

        Application Number
	
         

        Application Date

	
         

        PROBUPHINE
	
         

        Canada
	
         

        Titan Pharmaceuticals, Inc.
	
         

        1612370
	
         

        02/01/2013

	
         

        PROBUPHINE
	
         

        European Union
	
         

        Titan Pharmaceuticals, Inc.
	
         

        017362781
	
         

        10/18/2017

	
         

        PROBUPHINE
	
         

        Switzerland
	
         

        Titan Pharmaceuticals, Inc.
	
         

        629852017
	
         

        10/17/2017

	
         

        TITAN PHARMACEUTICALS
	
         

        United States of America
	
         

        Titan Pharmaceuticals, Inc.
	
         

        87/457,505
	
         

        05/19/2017

	
         

        PRONEURA
	
         

        United States of America
	
         

        Titan Pharmaceuticals, Inc.
	
         

        86/309,090
	
         

        06/13/2014

	
         

        PRONEURA
	
         

        Canada
	
         

        Titan Pharmaceuticals, Inc.
	
         

        1494136
	
         

        08/31/2010

	
         

        BUPLANT
	
         

        United States of America
	
         

        Titan Pharmaceuticals, Inc.
	
         

        87/009,766
	
         

        04/21/2016

	
         

        T & DESIGN

         

         
	
         

        United States of America
	
         

        Titan Pharmaceuticals, Inc.
	
         

        87/278,810
	
         

        12/22/2016









 






    -4-


     


    






 


	
         

        T & DESIGN

         

        
	
         

        Canada
	
         

        Titan Pharmaceuticals, Inc.
	
         

        1843050
	
         

        06/16/2017

	
         

        T & DESIGN

         

        
	
         

        European Union
	
         

        Titan Pharmaceuticals, Inc.
	
         

        IR1370158
	
         

        06/16/2017

	
         

        T & DESIGN

         

        
	
         

        Japan
	
         

        Titan Pharmaceuticals, Inc.
	
         

        IR1370158
	
         

        06/16/2017

	
         

        T & DESIGN

         

        
	
         

        Swtizerland
	
         

        Titan Pharmaceuticals, Inc.
	
         

        IR1370158
	
         

        06/16/2017

	
         

        TITAN PHARMACEUTICALS & DESIGN

         

        
	
         

        United States of America
	
         

        Titan Pharmaceuticals, Inc.
	
         

        87/278,812
	
         

        12/22/2016






 






    -5-


     


    

 


	
         

        TITAN PHARMACEUTICALS & DESIGN

         

        
	
         

        Canada
	
         

        Titan Pharmaceuticals, Inc.
	
         

        1843052
	
         

        06/16/2017

	
         

        TITAN PHARMACEUTICALS & DESIGN

         

        
	
         

        European Union
	
         

        Titan Pharmaceuticals, Inc.
	
         

        IR1366454
	
         

        06/16/2017

	
         

        TITAN PHARMACEUTICALS & DESIGN

         

        
	
         

        Japan
	
         

        Titan Pharmaceuticals, Inc.
	
         

        IR1366454
	
         

        06/16/2017

	
         

        TITAN PHARMACEUTICALS & DESIGN

         

        
	
         

        Switzerland
	
         

        Titan Pharmaceuticals, Inc.
	
         

        IR1366454
	
         

        06/16/2017



 








    -6-